Multithread effectively and personalize outreach to convert deals faster
Elevate social presence and drive business growth from social media
Identify and prioritize high-intent leads, and improve sales effectiveness
Find and connect with ICP attendees, and improve event outcomes
enClear Therapies is a pioneering clinical-stage biopharmaceutical company focused on developing transformative, disease-modifying therapies for complex neurodegenerative diseases. Their core mission is to address the significant unmet medical needs of patients suffering from conditions such as Amyotrophic Lateral Sclerosis (ALS), Alzheimer's disease, and Parkinson's disease. The company's innovative approach centers on clearing toxic proteins from the brain's glymphatic system using their proprietary EnClear-Clin™ platform technology, which involves a novel closed-loop cerebrospinal fluid (CSF) circulation system. By directly targeting the removal of these harmful proteins, enClear aims to halt or reverse disease progression, offering new hope to patients and their families.
The Cambridge headquarters serves as the central hub for enClear Therapies' research and development, clinical operations, corporate strategy, and administrative functions.
Situated in Kendall Square, the facility benefits from proximity to leading academic institutions, research organizations, and a dense network of biotech and pharmaceutical companies. It likely features modern laboratory and office spaces designed to foster collaboration and cutting-edge scientific research.
The work culture at enClear Therapies is characterized by a strong emphasis on scientific excellence, innovation, collaboration, and a patient-centric approach. Employees are typically mission-driven, dedicated to making a significant impact in the field of neurodegenerative diseases.
The Cambridge headquarters is critical to enClear's operations, providing access to top-tier talent, scientific collaborators, and resources essential for advancing its novel therapeutic platform and clinical programs.
While enClear Therapies' physical headquarters is in the US, its mission and operations have a global outlook. The company supports functions such as international clinical trial site management, collaborations with researchers and institutions worldwide, and aims for future global commercialization of its therapies to address neurodegenerative diseases that affect populations across the globe. They engage with the international scientific community to advance their research and development efforts.
245 First Street, Suite 1800
Cambridge
MA
USA
Address: N/A
N/A
Highperformr Signals uncover buying intent and give you clear insights to target the right accounts at the right time — helping your sales, marketing, and GTM teams close more deals, faster.
As of April 2025, EnClear Therapies' leadership includes:
EnClear Therapies has been backed by several prominent investors over the years, including:
enClear Therapies has focused on strengthening its leadership and governance. In the past 12 months (ending July 2024), a key development was the appointment of Dr. Paul L. Berns to its Board of Directors, bringing extensive biopharma experience. No major C-suite executive hires or departures have been publicly announced during this specific period.
Discover the tools EnClear Therapies uses. Highperformr reveals the technologies powering your target accounts — helping your sales, marketing, and GTM teams prioritize smarter and close faster.
Based on common patterns in the biopharmaceutical industry and data from professional networking platforms, enClear Therapies likely uses a standardized email format. The most probable primary format is [first_initial][last_name]@enclear-therapies.com.
[first_initial][last]@enclear-therapies.com
Format
adepasqua@enclear-therapies.com
Example
75%
Success rate
Business Wire • March 20, 2024
enClear Therapies announced the appointment of Paul L. Berns to its Board of Directors. Dr. Berns brings over three decades of experience in the biopharmaceutical sector, enhancing the company's strategic leadership....more
Business Wire • January 18, 2024
enClear Therapies reported the dosing of the first patient in its Phase 1 clinical study of EnCL-001, a novel therapy candidate for ALS. The study aims to evaluate the safety, tolerability, and pharmacokinetics of EnCL-001....more
See where a company’s workforce is located, by country or region.
View past and recent funding rounds with amounts and investors.
Understand company revenue estimates and financial scale.
Track active roles and hiring trends to spot growth signals.
Discover what a company offers—products, platforms, and solutions.
Get the company’s official SIC and NAICS classifications.
Analyze visitor volume, engagement, and top traffic sources.
Explore LinkedIn, Twitter, and other active social profiles.
Identify top competitors based on similar business traits.
Explore companies in depth — from the tech they use to recent funding, hiring trends, and buyer signals — all in one powerful view.
Highperformr AI helps you surface the right accounts and enrich your CRM with verified company and contact insights, so your teams can prioritize and engage faster.
Thousands of companies, including EnClear Therapies, are just a search away.